Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) saw a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 40,237 shares, an increase of 83.8% from the May 14th total of 21,893 shares. Based on an average daily volume of 4,758 shares, the short-interest ratio is presently 8.5 days.
Relief Therapeutics Trading Up 3.0%
Shares of RLFTF stock opened at $0.33 on Wednesday. Relief Therapeutics has a 12 month low of $0.32 and a 12 month high of $4.88. The business’s 50 day moving average is $0.45 and its two-hundred day moving average is $1.28.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Read More
- Five stocks we like better than Relief Therapeutics
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
